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Summary 
 We report the full cDNA sequence encoding the human homologue of murine 
PA2.26 (T1α-2, podoplanin), a small mucin-type transmembrane glycoprotein 
originally identified as a cell-surface antigen induced in keratinocytes during mouse 
skin carcinogenesis. The human PA2.26 gene is expressed as two transcripts of 0.9- and 
2.7-kb in several normal tissues, such as the placenta, skeletal muscle, heart and lung. 
Using a specific polyclonal antibody raised against a synthetic peptide of the protein 
ectodomain, PA2.26 was immunohistochemically detected in about 25% (15/61) of 
human early oral squamous cell carcinomas. PA2.26 distribution in the tumours was 
heterogeneous and often restricted to the invasive front. Double immunofluorescence 
and confocal microscopy analysis showed that PA2.26 colocalized with the membrane 
cytoskeleton linker ezrin at the surface of tumour cells, and that its presence in vivo was 
associated with downregulation of membrane E-cadherin protein expression. Ectopic 
expression of human PA2.26 in HeLa carcinoma cells and immortalized HaCaT 
keratinocytes promoted a redistribution of ezrin to the cell edges, the formation of cell-
surface protrusions, and reduced Ca2+-dependent cell-cell adhesiveness. These results 
point to PA2.26 as a novel biomarker for oral squamous cell carcinomas, that might be 
involved in migration/invasion.     
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Introduction 
Squamous cell carcinomas (SCCs) of the oral cavity, pharinx and larynx remain 
a significant public health problem. They represent 2-3% of all malignancies, and their 
incidence, particularly that of oral SCCs (OSCCs), is increasing in Western countries.1 
In spite of improved therapeutic procedures, the prognosis of OSCC patients is still poor 
and considerably lower than that of other neoplasias.2 This fact can be attributed to 
several factors: failure to respond to available chemotherapy, late presentation of the 
lesions, and lack of suitable markers for early detection and prognosis.3,4 Hence, the 
finding of novel tumour markers, particularly those associated with tumour cell invasion 
and spreading, can help provide a more accurate evaluation of prognosis and a more 
efficient management of the disease.  
PA2.26 antigen was identified in our laboratory as a cell-surface protein induced 
in murine epidermal keratinocytes and dermal fibroblast-like cells during wound 
healing and chemical carcinogenesis.5 Sequence analysis of the isolated cDNA and 
biochemical characterization of the protein revealed that murine PA2.26 is a small 
mucin-like transmembrane glycoprotein of about 45-kDa,6 highly homologous to the rat 
alveolar type I cell marker T1α and the podocyte-associated glycoprotein podoplanin.7,8 
Murine PA2.26 nucleotide sequence is almost identical to that of OTS-8 and gp38, 
markers of the osteoblastic cell lineage and stromal cells in peripheral lymphoid tissues, 
respectively,9,10 and completely matches the nucleotide sequence of RANDAM-2, a 
recently discovered membrane glycoprotein expressed in neuronal cells during mouse 
neurogenesis.11 Expression of PA2.26/T1α is developmentally regulated, and has also 
been detected in the choroid plexuses, ependyma, mesothelia, endothelia of lymphatic 
vessels and ciliary epithelia, located at the apical surface and microvillous 
projections.6,12 Other homologues include the rat glycoproteins RT140 and E11,13,14 the 
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canine receptor for the influenza C virus gp40 and its human homologue gp36,15,16 and 
the platelet aggregation-inducing sialoglycoprotein Aggrus.17 The generation of knock-
out mice containing a targeted mutation in the T1α/PA2.26 gene locus has provided 
important insights concerning the involvement of this glycoprotein in normal tissue 
development. T1α null mice die at birth due to respiratory failure caused by anomalies 
in the development of alveoli.18 These mice also showed defects in lymphatic, but not 
blood vessel pattern formation, associated with lymphedema, dilation of lymphatic 
vessels and diminished lymphatic transport.19 Although the precise function of 
Τ1α/podoplanin/PA2.26 in normal tissues is still unknown, T1α null mouse defects 
have been attributed to disruption of epithelial-mesenchymal signalling18 and to 
impaired cell to substratum adhesion and migration.19  
 Our previous studies suggested that induction of PA2.26 in mouse epidermal 
cells and tumours was related to cell migration and malignant progression.6,20 For this 
reason, we focused on characterizing the human homologue of mouse PA2.26, and on 
studying its involvement in human cancer. In the present work, we report the molecular 
characterization of human PA2.26. Both mouse and human PA2.26 exhibit similar 
structural and biochemical characteristics and, likely, share the same function. We show 
that PA2.26 is induced in a subset of human early OSCCs, associated with 
downregulation of membrane E-cadherin protein expression. Furthermore, PA2.26 
promotes the formation of cell-surface extensions and diminishes cell-cell adhesiveness 
when expressed in cultured human keratinocytes. These results suggest that PA2.26 





Materials and Methods 
 
Molecular characterization of PA2.26 cDNA 
 Mouse PA2.26 sequence was tested for similarity to known sequences deposited 
in the GenBank database using BLAST software.21 Four overlapping IMAGE cDNA 
clones: 41487, 154633, 881369 and 1031768 containing a cDNA sequence highly 
homologous to that of mouse PA2.26 were purchased from the Medical Research 
Council Center (Cambridge, UK, Human Genome Mapping Project) and sequenced 
with an ABI PRISM 377 machine (PE Applied Biosystems, Foster City, CA). A CpG 
rich region extending from exon 1 to intron 1 was predicted by the GRAIL/cpg program 
at the Human Genome Mapping Project (http://menu.hgmp.mrc.ac.uk/menu-
bin/Nix/Nix.pl). The chromosomal localization of the gene was performed by using the 
BLASTN and TBLASTN programs against the human genome (National Cancer for 
Biotechnology Information, NCBI). PA2.26 sequence was assigned to the NT_004577 
contig localized at 1p36.13. 
 
Plasmid construction 
 A partial human PA2.26 cDNA containing the full coding region was amplified 
from a human placenta cDNA library (Clontech Laboratories Inc. Palo Alto, CA) using 
the following oligonucleotides: 5’-CGGGATCGATGTGGAAGGTGTCAGC-3’ and 
5’-CCGCTCGAGGGCCACAGAAGTCAGAAACG-3’ (nucleotides 196-763 of the 
sequence reported in Fig. 1a). PCR conditions were 30 cycles: 95ºC for 1 minute, 59ºC 
for 1 minute and 72ºC for 1 minute. The resulting 568-bp cDNA fragment was cloned 
into the pGEM-T Easy vector (Promega Corporation, Madison, WI, USA), sequenced in 
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both directions, and subcloned into the pcDNA3 expression vector ((InVitrogen, San 
Diego, CA).  
 To express human PA2.26 fused to the N-terminal end of the enhanced green 
fluorescent protein (PA2.26-GFP), the PA2.26 cDNA fragment containing the full 
coding region was amplified by PCR using oligonucleotides: 5’-
GTGCTGGAATTCCCCGATGTGG-3’ and  5’-
TCAGGTACCCTGGGCGAGTACCTTCC-3’, that introduce an EcoRI site (GAATTC) 
at the 5’ end before codon 1 and a KpnI site (GGTACC) at the 3’ end, after codon 162, 
eliminating the stop codon. The product was subcloned into the pEGFP-N1 expression 
vector (Clontech). Sequencing confirmed the correct ligation of the PA2.26 cDNA 
fragment.  
 
Northern blot analysis 
Commercial Northern blots containing poly(A)+ RNA from adult human tissues 
(Clontech) were probed with PA2.26 and β-actin cDNAs according to the 
manufacturer’s instructions. The probe for PA2.26 was a fragment of 568-bp cloned 
from placenta (see above). 
 
Production of antibody  
A polyclonal Ab against human PA2.26 was raised in a rabbit by immunization 
with the synthetic peptide Leu-Glu-Gly-Gly-Val-Ala-Met-Pro-Gly-Ala-Glu-Asp-Asp-
Val-Val, comprising amino acids 37-51 of the protein ectodomain (P37-51), coupled to 
keyhole limpet hemocyanin (Isogen Bioscience BV, Maarssen, The Netherlands). A 
subcutaneous injection of 500 µg of P37-51 (333 µg of the protein carrier) in complete 
Freund’s adyuvant was given at multiple sites in the back of the animal, followed by 
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two booster injections in incomplete adyuvant at two-weeks and two-months intervals. 
The antiserum was concentrated by ammonium sulfate precipitation (50% saturation) 
and dialyzed against PBS/sodium azide. IgGs were purified by affinity chromatography 
through protein A-Sepharose 4B (Sigma-Aldrich, Madrid, Spain).  
 
In vitro transcription/translation reaction 
 The PA2.26 cDNA subcloned into the pcDNA3 vector was in vitro transcribed 
and translated in the TNT-coupled wheat germ or rabbit reticulocyte extract systems 
(Promega) according to the manufacturer’s instructions. The products of the reaction 
were fractioned on 12% SDS-PAGE gels and PA2.26 detected by Western blotting. 
 
cDNA transfection and cell culture conditions  
 HeLa and HaCaT cell lines were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum (Gibco Invitrogen Corp., Barcelona, 
Spain) and antibiotics (25 µg/ml amphotericin B, 100 µg/ml ampicillin, and 32 µg/ml 
gentamicin; Sigma-Aldrich, Madrid, Spain). Cultures were maintained on plastic plates 
at 37ºC in a 5% CO2 humidified atmosphere. HaCaT keratinocytes (passage 33) were 
kindly provided by Dr. Norbert E. Fusenig (German Cancer Research Center, 
Heidelberg, Germany). HeLa cells were obtained from the American Type Culture 
Collection (Rockville, MD, USA). 
For transient transfections, cells were seeded on glass coverslips 24 h before 
DNA transfer, and then transfected with the PA2.26 cDNA subcloned into the pcDNA3 
vector, using Effectene Transfection Reagent (Quiagen, Valencia, CA, USA). 
Immunofluorescence analysis was done 24 hours after transfection.  
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For stable transfections, cells cultured on plates were transfected with the 
PA2.26-EGFP construct or the empty pEGFP-N1 vector, as above. Transfected cells 
were selected by growing in DMEM containing 10% fetal calf serum and 0.5 mg/ml of 
G418 for 3-weeks. Individual clones were isolated with cloning rings, and characterized 
for  PA2.26 expression by flow cytometry analysis and Western blotting.  
 
Western blot analysis and glycosidase digestion 
For detection of PA2.26 in Western blots, cells or tissues (obtained from the 
“Hospital Universitario de la Princesa”, Madrid, Spain) were lysed in buffer RIPA 
(0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-
HCl, pH 8.0), and a cocktail of protease inhibitors (1 mM phenylmethylsulfonyl 
fluoride, 2 µg/ml aprotinin and 2 µg/ml leupeptin). Samples containing the same 
amount of protein (30 µg) were run on 10% or 7% SDS-PAGE and transferred to 
Immobilon P membranes (Millipore Corporation, Bedford, MA). Filters were 
immunoblotted with the PA2.26 Ab (at a dilution of 1:400 in PBS containing 1 mg/ml 
BSA) or preimmune serum at an equivalent dilution. As an additional control, the Ab 
was preincubated with an excess of either P37-51 (3 µg/ml) or an unrelated peptide (Gly-
Ala-Ser-Lys-Cys-Asp-Gly-Phe-Arg-Ser, Pcontrol) for 30 minutes. As secondary Ab, anti-
rabbit IgG coupled to horseradish peroxidase (Nordic Immunological Laboratories, 
Tilburg, The Netherlands) was used. For detection of E-cadherin and α-tubulin in 
Western blots, the mAbs ECCD-2 and DM1A (Sigma Aldrich) were used at 1:100 and 
1:10000 dilution, respectively. Peroxidase activity was detected using an enhanced 
chemiluminescence kit (ECL, Amersham Corporation, Arlington Heights, FL). 
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PA2.26 digestion with glycosidases was performed as previously described 6 in 
whole cell lysates (in buffer RIPA) obtained from HeLa cell transfectants, followed by 
Western blotting using the PA2.26 polyclonal Ab. 
 
Immunohistochemistry 
 Paraffin-embedded sections of OSCCs and premalignant lesions were obtained 
from the archive of the Department of Clinical Pathology at the “Hospital Universitario 
de la Princesa” (Madrid, Spain). OSCC patients did not receive any therapeutic 
treatment prior to local resection surgery. All cases were confirmed to have negative 
lymphatic nodes by histology and were therefore classified as intraoral-confined 
disease. Clinical follow-up data were retrieved from the oral carcinoma database of the 
Department of Oral and Maxillofacial Surgery, Hospital Universitario de la Princesa. 
The minimum follow-up period was 3 years. The mean follow-up was 5 years. 
PA2.26 immunostaining was performed directly in deparaffinized sections by 
either the Envision plus peroxidase method or the Labelled streptavidin-biotin (LSAB) 
2 system, alkaline phosphatase (Dako Cytomation Inc., Glostrup, Denmark) or the 
avidin-biotin alkaline phosphatase method. The Ab was used at 1:400 dilution before 
and after preincubation with P37-51 and Pcontrol peptides. Sections were dehydrated in 
graded ethanols, cleared in xylene, and mounted in Permount after counterstaining with 
hematoxylin and eosin. In all cases recorded as positive for PA2.26 immunostaining, 
labeling was proved to be blocked by preincubation of the Ab with P37-51. E-cadherin 
immunostaining in tumour sections was performed by heat-induced antigen retrieval in 
a press cooker with EDTA solution, pH 8.0, for 2 min, using mAb 4A2C7 at 1:500 
(Zymed Laboratories Inc., San Francisco, CA). 
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Confocal immunofluorescence microscopy analysis 
Double immunofluorescence detection of PA2.26 and ezrin in HaCaT and HeLa 
cells transiently transfected with PA2.26 cDNA was performed on cells fixed with 3.7% 
formaldehyde in PBS, permeabilized with 0.05% Triton X-100. PA2.26 polyclonal Ab 
(before and after preincubation with P37-51 and Pcontrol peptides, see above) and anti-ezrin 
mAb 3C12 (Sigma-Aldrich) were used at 1:100 dilution. FITC-labeled anti-rabbit or 
TRITC-labeled anti-mouse IgGs (Jackson, West Grove, PA) were used as secondary 
antibodies, respectively. For F-actin staining, phalloidin coupled to Rhodamin was used. 
Staining of nuclei was performed in a solution of 4’, 6-diamino-2-phenilindole (DAPI, 1 
µg/ml). 
Immunofluorescence detection of E-cadherin and β-catenin in PA2.26-EGFP stable 
transfectants was carried out on confluent cells grown on glass coverslips, fixed in cold 
methanol,22 using the mAbs 4A2C7 (Zymed Laboratories Inc.) and C19220 
(Transduction Laboratories, Lexington, KY) at 1:100 and 1:250 dilutions, respectively, 
and appropriate TRITC-labeled secondary Abs. 
Double-label immunofluorescence detection of PA2.26 and ezrin or E-cadherin in 
tumour sections was performed after heat-induced antigen retrieval and proteinase K 
digestion for 10 minutes at 37ºC. Sections were blocked in PBS containing 1% BSA 
and incubated with PA2.26 Ab and anti-ezrin 3C12 or anti-E-cadherin 4A2C7 mAbs. 
Alexa Fluor 588 goat anti-rabbit IgG or Alexa Fluor 594 goat anti-mouse IgG 
(Molecular Probes Europe BV, Leiden, The Netherlands) were used as secondary Abs. 
Tissue sections were then mounted in Mowiol and examined with a confocal 
microscope. 
Confocal laser scanning microscopy was performed with a Leica TCS-SP2 (Leica 
Lassertechnik GmbH, Heidelberg, Germany) adapted to an inverted Leitz DMIRB 
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microscope. Images were taken using a 63X (NA 1.4 oil) Leitz Plan-Apochromatic 
objective. 10-25 optical sections of 0.3 µm were made for three-dimensional 
reconstruction through the whole depth of the cells, and projections of 5-6 sections were 
used for reconstruction of particular cellular domains. For tissue samples, 12 optical 
sections of 0.5 µm were made. Images were assembled using Leica confocal software 
2.0. 
 
Cell aggregation assay 
Ca2+-dependent cell aggregation assays were performed according to Navarro 
and coworkers.22 Briefly, cell cultures were dissociated into single-cell suspensions 
under E-cadherin-saving conditions. Cells were suspended in 10 mM Hepes, pH 7.4, 
150 mM NaCl containing 0.5% BSA and 10 mM CaCl2 or 1 mM EGTA, and incubated 
under gyratory shaking at 80 rpm for 60 minutes. The degree of cell aggregation was 
expressed by the aggregation index: 1-(N60/N0), where N0 and N60 indicate the initial 
number of particles and the number of particles after 60 minutes of aggregation, 
respectively. All N0 and N60 measurements were done in duplicates, and the 
experiments were repeated at least twice. 
 
Results 
cDNA cloning, exon/intron organization, and chromosomal mapping 
 Several ESTs with significant homology to the mouse PA2.26 mRNA6 were 
identified by database comparison. Four overlapping IMAGE clones containing the full-
length cDNA were acquired from the Medical Research Council Center (Cambridge, 
UK, Human Genome Mapping Project) and their sequences determined. The 2737-nt 
cDNA obtained (Fig. 1a) contains a single polyadenylation consensus sequence 
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AATAAA and an open reading frame (ORF) encoding a 162 amino acid protein highly 
homologous to the 172-amino acid mouse PA2.26 protein. The human PA2.26 protein 
exhibits the typical structure of a type-I membrane mucin-like protein with an 
ectodomain containing a high proportion of potential O-glycosylation serine and 
threonine residues, and a presumptive spanning membrane domain followed by a short 
cytoplasmic tail of 9 amino acids (Fig. 1a and b). The cytoplasmic domain of the human 
protein conserves a cluster of three basic aminoacids (Fig. 1b) shared by transmembrane 
proteins of microvillal location23 that appears to be responsible for PA2.26 binding to 
proteins of the ezrin, radixin, moesin (ERM) family.6  
Database comparison of the complete 2737-nt cDNA sequence presented in Fig. 
1a revealed the presence of several ESTs belonging to the same transcriptional unit, 
further extending the 5’ UTR end by 8 nt (Access to GenBank BE563074/AA301065), 
by 37 nt (AU133042), and by 114 nt (BE887331), indicating the possible existence of 
other transcription initiation sites. Thus, a larger cDNA sequence registered in the 
GenBank (under accession number NP-006465) contains an alternative ATG start 
codon 5’ upstream of the sequence presented in Fig. 1a, predicting a new ORF, which 
includes de coding sequence reported here plus additional 76 N-terminal amino acids. 
We believe that this larger, alternative, polypeptide is unlikely to be expressed in human 
tissues because it lacks a signal peptide in the amino terminus for protein delivery to the 
plasma membrane, which is conserved in the mouse, rat and canine homologues.6,7,15 In 
addition, we show in this work that the size of the protein expressed by our cloned 
cDNA after transfection into mammalian cells coincides with that of the endogenous 
PA2.26 protein detected in human tissues by Western blotting (see below). The ORF 
encoding human PA2.26 is identical to that described for gp36 and T1α-2, the human 
homologues of canine gp40 and rat T1α, respectively.16,24 However, the reported gp36 
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and T1α-2 cDNA sequences are incomplete (768 and 865-bp, respectively) and have 
many changes in UTRs with respect to the PA2.26 sequence reported here. In addition, 
a 1013-bp cDNA sequence for human podoplanin has been delivered to GenBank 
(under accession number AF390106). This sequence is identical to that reported here for 
PA2.26 and corresponds to positions 21 to 1033 of the cDNA sequence showed in Fig. 
1a. 
 Alignment of the PA2.26 cDNA sequence with human genomic sequences 
deposited in GenBank predicts that the human PA2.26 gene contains 6 exons and 5 
introns. The lengths of introns and exons are shown in Fig.1c. All the intron-exon 
junctions follow the canonical AG-GT rules. The first exon contains the initiation codon 
ATG and a 5’ UTR of 203-nt. The last exon contains the termination codon followed by 
a 1769-nt UTR which includes a 200-nt AluSc sequence in the reverse orientation at the 
3’ end (Fig. 1a). The largest intron (> 22.746 nt) lies between exons 1 and 2. A 432-nt 
CpG island was predicted that comprises the last 182 nt of the exon 1 and the first 250 
nt of intron 1. We could assign the PA2.26 sequence to the NT_004577 contig localized 
to the short arm of chromosome 1 at 1p36.13.  
 
Expression studies in normal tissues  
Northern blot analysis with RNA isolated from various adult human tissues 
using a PA2.26 probe containing the full coding sequence amplified from a placenta 
cDNA library (see Materials and Methods), revealed two mRNA species of about 2.7-
kb and 0.9-kb (Fig. 2). The larger transcript corresponds to the estimated size of the 
full-length human PA2.26 cDNA presented in Fig. 1a. The origin of the 0.9-kb message 
is unknown at the present time. Clear expression of PA2.26 transcripts was observed in 
skeletal muscle, placenta and heart, and, at a lower level, in lung. The 2.7-kb transcript 
 14
was the most abundant of the two transcripts in the majority of these tissues. No specific 
signal could be detected in several other tissues, such as brain, liver, kidney and 
pancreas, even after long exposure of the autoradiography.  
 
Production of a specific polyclonal antibody 
Since our previous mAb generated against the mouse PA2.26 antigen6 was 
found not to recognize the human protein, we synthesized a peptide comprising amino 
acids 37-51 (P37-51) of the extracellular domain of human PA2.26, a region that does not 
contain glycosylation residues. This peptide was used to immunize rabbits (see 
Materials and Methods). To test whether the obtained polyclonal Ab recognized 
PA2.26, we synthesized the protein encoded by the PA2.26 cDNA by a coupled 
transcription/translation reaction using a cell-free wheat germ extract system. A 
polypeptide of about 21-kDa corresponding to the core protein of PA2.26 was 
synthesized, as detected in a Western blot (Fig. 3a). Preincubation of the Ab with P37-51, 
but not with an unrelated peptide (Pcontrol), prevented recognition of the 21-kDa 
polypeptide, indicating that the Ab was specific for the P37-51 amino acid sequence of 
PA2.26. The same result was obtained using a rabbit reticulocyte extract system to 
transcribe/translate the gene (data not shown). To test whether the Ab recognized the 
PA2.26 protein expressed in mammalian cells, PA2.26 cDNA was transfected into 
HeLa cells, which do not express endogenous PA2.26. As shown in Fig. 3b, the Ab 
specifically recognized a protein of about 38-40 kDa, which corresponds to the 
glycosylated mature form of PA2.26, as demonstrated by treatment with glycosidases 
(not shown). PA2.26 was neither expressed in parental HeLa cells nor in cells 
transfected with the empty vector. The Ab recognized a polypeptide of the expected 
size, 61 kDa, corresponding to PA2.26 expressed as a C-terminal fusion protein with 
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EGFP (PA2.26-EGFP, see Fig. 3d). To confirm the O-glycosylation of human PA2.26 
in the fusion protein, cell lysates were digested with glycosidases, followed by Western 
blotting with the PA2.26 Ab. Sequential digestion with neuraminidase and O-
glycosidase yielded a molecular mass reduction of about 11 kDa, while treatment with 
O-glycosidase alone did not affect the mobility of the protein (Fig. 3d), indicating that 
human PA2.26 protein is heavily O-glycosylated and contains sialic acid, just as the 
mouse PA2.26 protein.6 We also studied whether the Ab recognized the native PA2.26 
protein expressed in human tissues. As shown in Fig. 3c, protein forms of the same size 
as that of the exogenous PA2.26 protein expressed in HeLa cell transfectants were 
detected in placenta, lung and testis lysates by Western blotting, indicating that the 
protein encoded by the cloned cDNA has the same molecular mass than the endogenous 
PA2.26 protein. The level of PA2.26 protein expression in lung was lower compared 
with placenta and testis, which is in agreement with the Northern blot data (see Fig. 2). 
Testis (which was not screened for PA2.26 expression by Northern blot hybridization) 
was used in this assay because it proved to be positive for PA2.26 expression by 
immunohistochemistry (not shown).  
 
PA2.26 is expressed in oral squamous cell carcinomas 
 Since a preliminary RT-PCR analysis showed PA2.26 mRNA expression in 
some human OSCC cell lines (data not shown), we studied the expression of PA2.26 in 
primary oral tumours by immunohistochemistry. We found that PA2.26 is induced in 
about 25% (15 out of 61 cases) of early OSCCs located at floor of mouth and tongue 
(Table 1). A small number (n = 6) of gingival SCCs were also screened and found not to 
express PA2.26 (data not shown). No significant correlation was observed between 
PA2.26 expression and tumour differentiation grade (Table 1). No association was 
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found, either, between PA2.26 expression and clinical parameters, such as the age of 
patients, sex, survival and locoregional recurrence. For instance, the average age of 
patients included in the PA2.26-positive group was 52.00 + 10.39 (12 males and 3 
females) compared with 56.23 + 11.49 (38 males and 8 females) in the PA2.26-negative 
group. During the follow-up period (3 years minimum), the recurrence rate in the 
PA2.26-positive group was of 20% (3 out of 15), while the mortality rate due to tumour-
related causes was of 7% (1 out of 15), compared with 20% (9 out of 46) of patients 
who showed local or regional recurrences and 9% (4 out of 46) of patients dead in the 
PA2.26-negative group.  
PA2.26 expression in OSCCs was heterogeneous, often restricted to the growth 
front of the tumours (Fig. 4e), and was predominantly located at the plasma membrane 
(Fig. 4g). PA2.26 was neither detected in the normal oral epithelium (Fig. 4a), nor in 
premalignant lesions (n = 10) exhibiting moderate to intense dysplasia (Fig. 4b). 
However, a positive staining was seen frequently in the reactive mucosa adjacent to 
OSCCs, including those lesions stained weakly or not stained at all with the PA2.26 Ab 
(Fig. 4c and d). PA2.26 expression in the hyperplastic mucosa was restricted to basal-
like cells and no expression was seen in differentiating keratinocytes of suprabasal 
layers (Fig. 4d). Since mouse PA2.26 was found to destabilize E-cadherin-mediated cell 
to cell adhesions when expressed in keratinocytes20, sections from PA2.26-positive 
tumours were also stained with an anti-E-cadherin mAb. We found that E-cadherin 
expression in the tumours was also very heterogenous, with some areas showing an 
intense staining and others in which E-cadherin staining was fragmented or virtually 
absent (Fig. 4f, h). Interestingly, some regions that expressed PA2.26 seemed to exclude 
the presence of E-cadherin (Fig. 4, compare panels e and f). In other cases, PA2.26 
tended to be expressed in the layer of keratinocytes in contact with the stroma, while E-
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cadherin staining was mainly suprabasal (Fig. 4, compare panels g and h). Because of 
the preferential expression of PA2.26 in the basal layer of hyperplastic mucosa and 
tumour nests, we analyzed whether the presence of PA2.26 was restricted to 
proliferative cells by immunohistochemical staining with Ki-67, but no clear correlation 
between expression of this proliferation nuclear marker and that of PA2.26 was found 
(data not shown).     
The inverse correlation observed between PA2.26 and E-cadherin expression at 
the surface of carcinoma cells was further analyzed by double immunofluorescence and 
confocal microscopy studies in a representative number of PA2.26-positive SCCs of the 
tongue (n = 5). In all cases, E-cadherin protein was reduced or virtually absent at cell-
cell contacts in tumour nests that expressed PA2.26 (Fig. 5b-d). Conversely, a normal 
pattern of E-cadherin staining at cell-cell junctions was observed in regions that were 
negative for PA2.26 staining (insets in Fig. 5b-d). In contrast, PA2.26 and ezrin focally 
colocalized in vivo at the plasma membrane of tumour cells (Fig. 5f-h and insets). These 
results suggest that expression of PA2.26 in OSCCs might be associated with 
destabilization of E-cadherin-mediated cell-cell adhesion. 
 
PA2.26 induces cell-surface protrusions and reduces cell-cell adhesiveness   
To analyze the effects of PA2.26 expression on the phenotype of human 
epithelial cells, we transiently transfected HeLa carcinoma cells and HaCaT 
immortalized keratinocytes with the human PA2.26 cDNA, since these cell lines were 
previously found not to express PA2.26 mRNA by RT-PCR (data not shown). 
Immunofluorescence staining and confocal microscopy analysis showed that PA2.26 
protein was directed to the cell surface (Fig. 6). Vertical optical sections indicated that 
PA2.26 was distributed in a clustered pattern all over the plasma membrane (Fig. 6c and 
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d), suggesting that the antigen was concentrated at cell-surface protrusions. This was 
confirmed with a three-dimensional reconstruction of the upper part of transfected cells 
(Figure 6a and b). We also studied by double immunofluorescence analysis whether 
human PA2.26 colocalized with ezrin at plasma membrane protrusions. Ezrin was 
located as a punctate staining distributed uniformly throughout (underneath) the plasma 
membrane in HeLa cells that did not express PA2.26 (Fig. 6f and g), in a pattern typical 
of microvilli.25 However, in cells expressing PA2.26, ezrin was relocated to the cell 
edges where it colocalized with PA2.26 on membrane projections (Fig. 6e-g). A similar 
effect, although less pronounced, was observed in HaCaT cell transfectants (Fig. 6h-j). 
This milder effect could be due to the lower PA2.26 expression level at the cell surface 
obtained in this latter cell line. In contrast to HeLa, expression of PA2.26 in HaCaT 
keratinocytes was unstable, as suggested by the presence of many transfectant cells with 
endocytic vesicles containing PA2.26 (data not shown). Both the density and length of 
projections protruding from the cell edges appeared to be enhanced in transfected cells 
with respect to the non-transfected ones (Fig. 6e-j, arrows). Many of these PA2.26-
containing projections had lengths of >5 µm (insets in Fig. 6e-g), and formed 
phalloidin-positive F-actin bundles at the periphery (not shown), resembling 
filopodia.26,27 In contrast, in cells that did not express PA2.26, most of ezrin-positive 
cell-surface protrusions were microvilli or microspikes (<5 µm).  
Since HeLa are not cohesive cells and have lost E-cadherin expression,28,29 we 
studied the effect of PA2.26 on cell-cell adhesiveness in HaCaT keratinocytes. To this 
aim, HaCaT cells were stably transfected with a vector encoding PA2.26 fused to EGFP 
(PA2.26-EGFP). This procedure resulted in a more stable expression of PA2.26 at the 
cell surface when compared to the above transfection experiment. PA2.26-EGFP was 
also directed to cell-surface projections (Fig. 7f), where it colocalized with ezrin and F-
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actin (not shown), while EGFP was distributed uniformly throughout the cytoplasm in 
control cells transfected with the empty vector (inset in Fig. 7b). Control transfectants 
grown at confluence showed the typical tight cell-cell contacts of keratinocytes (Fig. 
7a), decorated by a continuous line of E-cadherin and β-catenin staining (Fig. 7c and d). 
In contrast, aberrant cell-cell borders with irregular outlines (Fig. 7e), and intercellular 
spaces filled with PA2.26-containing microvilli (Fig.7f and inset), were observed in 
PA2.26-EGFP transfectants. These cells showed a rather disorganized pattern of E-
cadherin and β-catenin distribution, characterized by the presence of both proteins out 
of cell-cell contacts (Fig. 7g-h and insets).  
To ascertain whether expression of PA2.26 in HaCaT keratinocytes impaired E-
cadherin function, a Ca2+-dependent cell aggregation assay was performed in selected 
clones expressing varying amounts of PA2.26-EGFP (Fig. 8). Ca2+-dependent cell-cell 
adhesiveness decreased in PA2.26-EGFP transfectants in comparison with the parental 
cell line or control cells (Fig 8b and c), in direct proportion to the level of PA2.26-
EGFP expression (Fig 8a). Although a slight reduction of E-cadherin protein levels was 
found in PA2.26-EGFP transfectants with respect to control cells, it did not correlate 
with the level of PA2.26-EGFP expression (Fig. 8a), suggesting that PA2.26 reduces 
HaCaT cell-cell adhesiveness by a mechanism that does not necessarily involve 
downregulation of E-cadherin expression.  
 
Discussion 
We report in this article the full cDNA sequence of the human homologue of 
murine PA2.26 antigen. The human PA2.26 gene is expressed as two mRNAs of 2.7- 
and 0.9-kb in the placenta, heart, skeletal muscle and lung. These two transcripts have 
also been reported for podoplanin in human lymphatic endothelial cells.30 The size of 
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the larger mRNA detected in human tissues by Northern blot hybridization fits the 
length of the cDNA reported here for PA2.26. It encodes a small mucin-type 
transmembrane glycoprotein of 162 amino acids practically identical to T1α-2, gp36 
and podoplanin16,24, which is detected as a 38-40-kDa protein form in transfected cells 
and human tissue lysates in Western blots, using a polyclonal Ab raised against a 
peptide of the ectodomain. Nevertheless, the presence of an alternative mRNA of 0.9-kb 
in human tissues might suggest the existence of other protein isoforms not detected by 
this Ab.   
The main finding of this study is that expression of PA2.26 (Τ1α, podoplanin) is 
induced in a subset of human early OSCCs. This observation strengthens our previous 
work showing the induction of PA2.26 during mouse skin carcinogenesis related to cell 
migration and invasion/metastasis. 5,6,20 Both, oral and skin carcinogenesis are multistep 
processes in which multiple genetic events lead to the disruption of normal regulatory 
pathways controlling cell division, differentiation and cell death.31,32 SCCs are 
characterized by their ability to spread locally and regionally, and tumour infiltration 
involves, among other factors, alterations in the expression and/or function of cell 
adhesion molecules, such as E-cadherin.33,34 Reduced expression of E-cadherin and β-
catenin at the plasma membrane have been found in OSCCs associated with the degree 
of tumour differentiation and poor prognosis.34-37 Thus, expression of E-cadherin is 
homogeneously reduced at late stages in poorly differentiated carcinomas, apparently by 
a mechanism that involves hypermethylation of the gene promoter.38-40 However, well 
and moderately differentiated OSCCs often show a partial loss of membrane E-cadherin 
and β-catenin expression, circumscribed to some tumour regions or even to certain areas 
of tumour nests.34,35 PA2.26 expression in early OSCCs is heterogeneous and 
fragmented, frequently restricted to the invasive tumour front, and correlates with 
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reduced membrane E-cadherin expression in vivo and with impaired cell-cell 
adhesiveness in vitro. These results suggest that the presence of PA2.26 in OSCCs can 
be related to a migratory/invasive phenotype.  
The effect of PA2.26 on cell-cell adhesiveness appears to be indirect, involving 
the reorganization of the actin cytoskeleton by recruitment of ezrin and the induction of 
cell-surface protrusions. The ERM proteins have been implicated in the organization of 
specialized membrane domains, and in the control of cell shape, cell adhesion and 
migration, by linking transmembrane proteins to the actin cytoskeleton.25,41 Mouse 
PA2.26 was shown to coimmunoprecipitate with ezrin and moesin,6 and a 
yuxtamembrane cluster of basic amino acids which appears to be responsible for murine 
PA2.26 binding to ERM proteins is conserved in the human PA2.26 endodomain. In 
fact, human PA2.26 colocalizes with ezrin in vivo at the surface of oral carcinoma cells 
and at membrane projections of HeLa and HaCaT cell transfectants. It is likely that 
PA2.26-induced redistribution of ezrin and formation of cell-surface extensions disrupt 
the anchorage of E-cadherin-catenin complexes to the cortical actin cytoskeleton. 
Interestingly, Pujuguet and coworkers show in a recent report that a constitutively active 
mutant form of ezrin, when expressed in cultured epithelial cells, causes extensive 
lamellipodia formation and disturbs E-cadherin-dependent cell-cell contacts via 
activation of Rac1, but not of other Rho GTPases.42 These results suggest a role of ezrin 
in cell-cell junction assembly. Whether the effects of PA2.26 on the cell membrane and 
cytoskeleton involve changes in the activity of Rho GTPases is currently being 
investigated. Ectopic expression of mouse PA2.26 in premalignant murine keratinocytes 
(MCA3D cell line) elicited a complete epithelial-mesenchymal transition, with loss of 
E-cadherin protein (but not mRNA) expression, and acquisition of a fibroblast-like 
morphology associated with development of undifferentiated carcinomas.6,20 In contrast, 
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human PA2.26 expressed in immortal HaCaT keratinocytes failed to trigger a complete 
epithelial-mesenchymal transition, but induced cell scattering associated with increased 
plasma membrane motility and reduced cell-cell cohesion. To explain this apparent 
discrepancy, it should be noted that HaCaT keratinocytes are nontumorigenic when 
injected subcutaneously or grafted as surface transplants onto nude mice, and, therefore, 
represent a preneoplastic stage of tumour development43. MCA3D keratinocytes, on the 
other hand, can develop tumours in skin graft experiments and are considered a 
premalignant cell line,20 a step further in tumour progression compared with HaCaT 
cells. Consequently, it is likely that PA2.26 needs to cooperate with other genetic or 
epigenetic events to confer a full malignant phenotype in keratinocytes. 
Similar effects on the plasma membrane and cell-cell adhesiveness have been 
recently found for dysadherin, a different mucin-type glycoprotein of 178 amino acids, 
also associated with cancer. Transfection of dysadherin cDNA into liver cancer cells 
resulted in formation of numerous microvilli and impaired cell-cell adhesiveness 
without affecting E-cadherin mRNA expression.44 In contrast with other known cancer 
anti-adhesive mucins of very large molecular masses (> 200 kDa), such as MUC1 
(episialin) and MUC4 (sialomucin),45,46 PA2.26 and dysadherin belong to a group of 
cancer membrane mucins characterized by their relatively small size. Both PA2.26 and 
dysadherin appear to downregulate E-cadherin function in carcinoma cells by a novel 
mechanism involving a reorganization of the actin cytoskeleton. 
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Legends to Figures 
 
Figure 1. (a) Nucleotide sequence and predicted protein product of human PA2.26 
cDNA. The vertical arrows indicate the exon-intron junctions. The N-terminal signal 
sequence is underlined and the membrane-spanning domain is shaded. Boldface amino 
acids represent the peptide sequence (P37-51) used for immunization in order to raise a 
PA2.26 polyclonal Ab. A partial AluSc sequence at the 3’ end is in boldface and italics. 
The highly conserved AATAAA polyadenylation signal sequence is indicated. The 
sequence is available from GenBank under accesion number AY194238. (b) Schematic 
representation of mouse and human PA2.26 protein domains. SP, signal peptide; ECTO, 
ectodomain; TM, transmembrane domain; ENDO, endodomain. Percentages indicate 
identical residues in the mouse and human polypeptides. A cluster of basic amino acids 
(underlined) potentially responsible for binding to ERM proteins and a potential protein 
kinase A/protein kinase C-dependent phosphorylation Ser (bolded) are conserved in the 
mouse and human PA2.26 endodomains. (c) Schematic representation of the PA2.26 
exon-intron structure. Boxes represent exons and open boxes contain untranslated 
regions. The dotted zone indicates the position of the AluSc sequence. The sizes of 
exons and introns are indicated in bp and kb, respectively. 
 
Figure 2. Analysis of PA2.26 mRNA expression in human tissues. Multi-tissue 
Northern blot hybridization revealed two mRNA bands of around 2.7-kb and 0.9-kb in 
size in skeletal muscle, placenta, heart and lung. A β-actin probe was used as a control 
for RNA quality and amount.  
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Figure 3. Characterization of the human PA2.26 cDNA product. (a) In vitro 
transcription/translation of PA2.26 cDNA using a TNT-coupled wheat germ extract 
system. The products of the reaction with and without (input) PA2.26 cDNA subcloned 
into the pcDNA3 vector were subjected to Western blot using PA2.26 Ab preincubated 
with P37-51 or an unrelated peptide (Pcontrol). (b) Specific detection of PA2.26 protein in 
HeLa cells transfected with PA2.26 cDNA by Western blot analysis as in panel a. 
Immunodetection of α-tubulin was used as a control for protein loading. (c) Comparison 
of molecular masses of exogenous PA2.26 protein expressed in HeLa cells and 
endogenous PA2.26 protein detected in human tissues by Western blotting. (d) 
Detection of PA2.26-EGFP in HeLa cells transfected with a PA2.26-EGFP fusion 
construct before and after treatment with neuraminidase (Na) and O-glycosidase (O-
Gly) by Western blotting using PA2.26 Ab.  
 
Figure 4. Immunohistochemical detection of PA2.26 in human OSCCs. (a) Normal oral 
epithelium. PA2.26 is absent from all epithelial layers (e) but present in lymphatic 
vessels (lv) and interstitial fibroblast-like cells (arrows) in the underlying connective 
tissue. (b) Carcinoma in situ showing no immunoreactivity to PA2.26 Ab. A stained 
lymphatic vessel (lv) in the edge of the tumour serves as a positive control. (c, d) 
Hyperplastic mucosa adjacent to a SCC weakly stained for PA2.26 showing strong 
PA2.26 immunoreactivity in the basal layer. Panel d shows a higher magnification of 
the region marked in panel c; tn, tumor nest; e, epithelium. (e, f) Sections of a SCC 
(tongue) stained with PA2.26 (e) and E-cadherin (f) Abs. The tumour shows a strong 
PA2.26 staining in its invasive front (panel e), while E-cadherin is virtually absent from 
this area (panel f). (g, h) Sections of a SCC showing patchy and heterogeneous PA2.26 
(g) and E-cadherin (h) staining. PA2.26 is mainly concentrated at the plasma membrane 
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of carcinoma cells in contact with the stroma (g), while E-cadherin staining tends to be 
suprabasal (h).  
 
Figure 5. Confocal immunofluorescence colocalization of PA2.26 with E-cadherin (b-
d) and ezrin (f-h) in OSCCs. Panels b-d and f-h show fluorescence localization of the 
indicated proteins in tumour sections. Colocalization is visualized by yellow colour. 
Panels a and e show PA2.26 immunohistochemical staining of sections from the same 
tumours as in b-d and f-h, respectively. Note in panels b-d reduced or absent E-cadherin 
staining in carcinoma cells expressing PA2.26. Insets in these panels show a tumour 
region which is negative for PA2.26 staining and exhibits normal E-cadherin 
expression.  Arrowhead in panel e indicates the zone showed in panels f-h. Note in 
panels f-h that PA2.26 colocalizes with ezrin at the plasma membrane of carcinoma 
cells. Some PA2.26-stained, ezrin-negative cells are also seen in the stroma. Insets in 
panels  f-h show a higher magnification of the area marked with asterisk. Bars, 20 µm. 
 
Figure 6. Confocal immunofluorescence localization of human PA2.26 and ezrin in 
HeLa and HaCaT cells transiently transfected with PA2.26 cDNA. (a, b)  Maximum 
projections of horizontal (xy) optical sections through the whole depth (a) or the apical 
domain (b) of HeLa and HaCaT cell transfectants, respectively, stained with PA2.26 
Ab. (c, f) Vertical (xz) optical sections obtained in panels a and b (discontinuous line), 
respectively. Note PA2.26 localization at plasma membrane protrusions. (e-j) 
Immunofluorescence colocalization of PA2.26 and ezrin in HeLa (e-g) and HaCaT (h-j) 
cell transfectants. Three-dimensional projections of confocal horizontal sections made 
in PA2.26 (green) and ezrin (red) stained cells are shown. PA2.26 and ezrin colocalize 
(yellow) at plasma membrane protrusions in reconstructions of dual colour horizontal 
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sections (c and j). Note a clear redistribution of ezrin to the cell borders in transfected 
cells. Many PA2.26-containing protrusions (arrows) have lengths > 8 µm resembling 
filopodia (insets in panels e-g), while ezrin in PA2.26 non-expressing cells decorates 
microvilli or microspikes. Nuclei were stained with DAPI. Bars, 20 µm (a, b, h-j); 8 µm 
(e-g and insets). 
 
Figure 7. Confocal immunofluorescence localization of E-cadherin and β-catenin in 
HaCaT-EGFP (a-d) and HaCaT-PA2.26-EGFP (e-h) stable transfectants grown at 
confluence. Panels a and e show phase contrast micrographs of HaCaT keratinocytes 
transfected with EGFP (Ha-EGFP) and PA2.26-EGFP (Ha-2.26-EGFP) fusion 
construct, respectively. Panels b-d and f-h show fluorescence localization of the 
indicated proteins in cells fixed in methanol (in order to better visualize E-cadherin and 
β-catenin staining), except for cells in inset of panel b that were fixed in formaldehyde 
(in order to see EGFP subcellular localization). EGFP is distributed uniformly through 
the cytoplasm as a soluble protein (panel b and inset) that is eliminated in cells fixed in 
methanol (panel b). Insets in panels c, d, g and h show higher magnifications of cell-cell 
borders. E-cadherin and β-catenin were detected by indirect immunofluorescence using 
specific mAbs. PA2.26-EGFP is directed to the plasma membrane and membrane 
protrusions (f and inset). Note perturbed distribution of E-cadherin and β-catenin with 
presence of the proteins out of cell-cell contacts in PA2.26-EGFP with respect to EGFP 
transfectants. Bars, 100 µm (a, e), 40 µm (b-d, f-h). 
 
Figure 8. Expression of PA2.26-EGFP inhibits E-cadherin function in HaCaT 
keratinocytes. (a) Expression of PA2.26-EGFP and E-cadherin proteins in parental 
cells, EGFP transfectants (Ha-EGFP-c7) and PA2.26-EGFP transfectants (Ha-2.26-
 33
EGFP-p6, -p7, -c7, -c11) by Western blotting using PA2.26 Ab and a specific anti-E-
cadherin mAb. The filter was reblotted with an anti-α-tubulin mAb as a control for 
protein loading. (b) Ca2+-dependent cell aggregation in HaCaT and transfectant cells as 
shown by the aggregation index determined after 60 minutes of incubation in the 
presence of 10 mM Ca2+, as described in Materials and Methods. The aggregation index 
is expressed normalized to that obtained in the presence of EGTA. (c) Phase contrast 
micrographs of cell aggregates obtained after 60 min of incubation in the absence 
(EGTA) or presence of Ca2+. Bars, 100 µm. 
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TABLE 1 – EXPRESSION OF PA2.26 IN HUMAN ORAL SQUAMOUS 
CELL CARCINOMAS 
----------------------------------------------------------------------------------------------- 
Site   Cases   Number of cases showing positive  
reactivity to PA2.26 antibody  
----------------------------------------------------------------------------------------------- 
Floor of mouth 26    8 (31%) 
 
Tongue  35    7 (20%) 
----------------------------------------------------------------------------------------------- 
 TOTAL   61    15 (25%) 
 ----------------------------------------------------------------------------------------------- 
 Stage Ia  22    4 (18%) 
  
 Stage II  39    11 (28%)  
 ----------------------------------------------------------------------------------------------- 
 WDb   27     7 (26%) 
 MD   34     8 (24%) 
-----------------------------------------------------------------------------------------------  
aStage 1: T1, tumor 2 cm or less in greatest dimension; N0, no regional lymph 
node metastasis; M0, no distant metastasis. Stage II: T2, tumor size between 2 to 
4 cm; N0; M0.  
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      Ala Ser Thr Gly Gln Pro Glu Asp Asp Thr Glu Thr Thr Gly Leu Glu Gly Gly Val Ala Met Pro   44 
 270  GCC AGC ACA GGC CAG CCA GAA GAT GAC ACT GAG ACT ACA GGT TTG GAA GGC GGC GTT GCC ATG CCA  
 
      Gly Ala Glu Asp Asp Val Val Thr Pro Gly Thr Ser Glu Asp Arg Tyr Lys Ser Gly Leu Thr Thr   66 
 336  GGT GCC GAA GAT GAT GTG GTG ACT CCA GGA ACC AGC GAA GAC CGC TAT AAG TCT GGC TTG ACA ACT  
 
      Leu Val Ala Thr Ser Val Asn Ser Val Thr Gly Ile Arg Ile Glu Asp Leu Pro Thr Ser Glu Ser   88 
 402  CTG GTG GCA ACA AGT GTC AAC AGT GTA ACA GGC ATT CGC ATC GAG GAT CTG CCA ACT TCA GAA AGC  
 
      Thr Val His Ala Gln Glu Gln Ser Pro Ser Ala Thr Ala Ser Asn Val Ala Thr Ser His Ser Thr  110 
 468  ACA GTC CAC GCG CAA GAA CAA AGT CCA AGC GCC ACA GCC TCA AAC GTG GCC ACC AGT CAC TCC ACG  
 
      Glu Lys Val Asp Gly Asp Thr Gln Thr Thr Val Glu Lys Asp Gly Leu Ser Thr Val Thr Leu Val  132 
 534  GAG AAA GTG GAT GGA GAC ACA CAG ACA ACA GTT GAG AAA GAT GGT TTG TCA ACA GTG ACC CTG GTT  
 
      Gly Ile Ile Val Gly Val Leu Leu Ala Ile Gly Phe Ile Gly Gly Ile Ile Val Val Val Met Arg  154 
 600  GGA ATC ATA GTT GGG GTC TTA CTA GCC ATC GGC TTC ATT GGT GGA ATC ATC GTT GTG GTT ATG CGA  
 
      Lys Met Ser Gly Arg Tyr Ser Pro Stop                                                     162 
 666  AAA ATG TCG GGA AGG TAC TCG CCC TAA AGAGCTGAAGGGTTACGCCCTGCTGCCAACGTGCTTAAAAAAAGACCGTTT 
 
 744  CTGACTCTGTGCCCTGTCCCTGAGCTCGTGGGAGAAGATGACCCGTGGAACACTTGCCTGGCCCACTCAGAATCCACGGTGACCTCT 
 831  CCGCTTGCCAAAATAACCGAAGGAAAGACCGTTCACCAGACTTGGCTCCTCTAAACATTTGCTGTTCAAACATGTTTTTGAATATAC 
 918  ATTCTATAAAAGATTATTTGAAAGACAAAATTCATAGAAAATGGAGCAAAACTGTATAAACTGATTTGTAACTAACACTGGACCATT 
1005  GGATCGATATTATATGCTGTAACCATGTGTCTCCGTCTGACCATTCTTGTTATTGTTAAAATGCAGAGGAATCTGGAAATATTTATA 
1092  TCCACGGAGTCCTTGGATCCAGTGCTACGTCAGTAAATAGCACCAGCATTTTGCAATTGCTGATCTGCTGAAATGTACACATTCTGG 
1179  TCTAGTTTGGTCTATCTTTTAAAGCCTGATCTGGTGTGAATAATCAACTAGGAAATCTAAACTTGGATAACACGTGGTGAACAACTG 
1266  CCTTTAGCTGGTCCAGATTAATCATTTCAAAGACATCCATTTTAGATCACAAGCAGGAAGTCGATAGTCTCAAAGGCACTTTGTTTC 
1353  TCCCAAGTAGGCCACCAGGCAGCCTCTAGAGTTGCTTTACCCAAATCCTTCTCCAGCCATGACTTGGTGACTCTAAGCTTGCTCCCA 
1440  CCTGCCCCCTCCACTTCCCTCAGATGATGAGGAGCCAGGGCTAAGGGGGCAGCCTTCTCTCTTCCCAGTGATGCACATCCTTCACAT 
1527  TGGCTGCTTTGTTCTGGAATATGGATATCTCAGCCTGGATGCCGAGGAAGCTGCTGGATGCTTAATGGTGCTAGAGGCTCAAGTGTG 
1614  TTTGAAACCAAGAGCCAGTTGTCCCCCATGCAGAAAGAAATCCTGTGTGAGCCTCTGGTATGAGAAATAAAATCTGCCAGTTTTATA 
1701  ACATTCACTTTCTGCCTCTGAGGAAAGATACAGGGAACAAAAATCAATTTGTACAGTCTTAATATTAAAAGCAGCTTGACTAAATAC 
1788  CTGATTTAAAAATAGAAGACATCCCCAGTCCTCATGACATACCGCAAATATCTGTGGGGTCCTGTTGAAAAGAACAAAATAAAGGAG 
1875  CCCAAGGGGTCATTCTGTCTCAGCACCATCCAGCCTGGCACTTCTCTTCCCATATATCCATTGGATTTTTTTTTTTTTTCCTAAACA 
1962  AAGTTTTTACACTGAGCAGATGCTCTGTCATGATGGCGGTTGTGCAATTCTGGTATCCTCTAAATTTGTAAGCATTCATAAAACAGG 
2049  AAAAAGTAAACTATCATTCGGAAGCACAGCCCATTCCTCCCATTTTTTGCAATGATGTCTGGATGTTATTTTAAACAGTGTGTCTGT 
2136  GTGTTCCCAAATCCAGCTGGCCCCACCAGCTCAGATTCCATTTTTTTTGTGTGTGTGTGTGAAACGTAGTCTGCAACTCTGCCTCCC 
2223  GGCAATTATACATGTGTCAGGATGTCAAAAAGCAATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGTTCCTACCACCAC 
2310  ACCCGGCCAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCGTATCGGCGAGGATGATCTCTATCTCTTGACCTCGTGATCTGCC 
2397  CGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGTGCCACTGCGCTCGGCCTCAGATTCCATATTTGAACACCAGCTGATTGAG 
2484  AGAAGGGGAATGAGAAGAGCTGGATGAGTTTAAATAACTCATTGTTCAGATTCCTGAACAGGAGTTGGGATAATGGCCATCTTTTCT 
2571  TTCCTATCCTTTCTTCCCCCCTCACTGTGAAAAATAACAGTCCACCCCAAGTCATACACTGGACCCAGTGCCTGCGGGGACAGGACT 












Martin-Villar et al. Figure1 
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Martín-Villar et al. Figure 4




























































































































Martin-Villar et al. Figure 8
0 0,2 0,4 0,6 0,8 1
Ha-2.26-EGFP-c11
Ha-2.26-EGFP-c7
Ha-2.26-EGFP-p7
Ha-2.26-EGFP-p6
Ha-EGFP-c7
HaCaT
1-(N60/N0)
